Letter to the FDA Urging That the Composition of the Advisory Committee for the Upcoming Hearing on the Proposal to Withdraw Approval of Hydroxyprogesterone (Makena) Be Fairly Balanced

View as PDF

View press release

Public Citizen urged the Food and Drug Administration (FDA) to make sure that the advisory committee for a planned agency hearing that will consider the agency’s proposal to withdraw the drug hydroxyprogesterone (Makena), which is approved to reduce the risk of preterm birth, from the market is fairly balanced to ensure the integrity of the hearing process and public trust in the committee’s advice and recommendations.

See Public Citizen’s other work on hydroxyprogesterone caproate (Makena).